

MICHAEL J. GONZALEZ FOUNDATION, INC.

MEGA-VITALITY

Metabolic Energy Generating ATP

Current #90

Joe Tippens

Support your body while it is still strong.

A patient who spoke

Joe Tippens was a patient who spoke when speaking was costly. That is courage. It is not a protocol. Fenbendazole is not a MEGA pillar and it is not MEGA-ATP. He was also on a Keytruda trial. One story is not a trial. The oncologist stays in the chair.

Makis was the search. This page is the patient door. Do not merge them into a stack. Eat is still the plate.

Courage is not a paste

His layer	Not this page
A patient who spoke in public.	A Foundation fenbendazole protocol.
Courage named. The chair stays.	Panacur. Safeguard. Onco Adjunct.
A trial drug named as a confounder.	A reason to skip licensed oncology.
Correction remains the how — #52.	A patient forum we run.

What the layer taught

If one person speaks, thank the courage. Then keep the licensed chair. Liver injury is a named weather. RFK Jr. is next — a public voice that would not row for the ship.

How you keep it

Keep Eat. Keep the oncologist. If a question is a molecule from a story, take it to someone licensed who knows you. Do not dose from a Current.

Be brave enough to thank a speaker without swallowing the story as medicine

You are not behind if you never read that blog. You are not too late. Your mills are still minting every second of every day. Feed them. Courage is a layer. It is not Tuesday.

The question

Will you honor a patient who spoke — and still keep the oncologist in the chair? The answer is yours. You can take it. You can leave it. No one can take it for you.

If you take it, eat tonight. That is Tippens, kept as courage — not as a paste.

If you want to keep learning, keep flowing with our Currents. RFK Jr. is next.

Notes

- This is education. It does not diagnose, treat, or claim to cure cancer. It does not print a fenbendazole dose.

- It does not replace your physician, your oncologist, your medications, or the care you already have. Do not add, stop, or delay licensed oncology from this page.
- Concurrent Keytruda in the public story is a named confounder. The SCLC indication for that drug was later withdrawn after KEYNOTE-604 missed overall survival. Case reports of drug-induced liver injury are a hard stop to self-dosing.
- The Foundation does not sell Panacur, Safeguard, or Onco Adjunct. It does not run a patient forum. Public language stays Metabolic Correction.

Support your body while it is still strong.

Michael J. Gonzalez Foundation, Inc.